Diseases /
Colorectal Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa. The vast majority are adenocarcinomas. [1]
Biomarker-Directed Therapies
Of the biomarker-directed therapies for colorectal carcinoma, 6 are FDA-approved in at least one setting and 11 have NCCN guidelines in at least one setting [3].
Cetuximab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must not match any of the following:
BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
| Note: Recommended for tumors with wild-type KRAS/NRAS (codons 12, 13, 59, 61, 117, and 146), and absence of BRAF V600E. |
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely. Joint guidance from ASCO, AMP, CAP, and ASCP makes no recommendation for or against BRAF status as a predictive molecular biomarker, citing insufficient evidence. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely. The detected alteration (V600_K601delinsE) includes the V600E change plus a deletion of the adjacent amino acid, and in vitro evidence identifies it as a gain of function mutation, similar to V600E alone. Joint guidance from ASCO, AMP, CAP, and ASCP makes no recommendation for or against BRAF status as a predictive molecular biomarker, citing insufficient evidence. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (MCG) |
| Note: Preclinical studies and limited retrospective data suggest that KRAS amplification confers resistance to anti-EGFR antibodies. |
Fam-Trastuzumab Deruxtecan +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Clinical Setting(s): Metastatic (NCCN) |
| Note: NCCN recommended as subsequent line therapy. |
Fluorouracil +
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (NCCN) |
| Note: According to NCCN, stage II MSI-H patients do not benefit from 5-FU adjuvant therapy. |
Irinotecan +
Nivolumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Approved for patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a uoropyrimidine, oxaliplatin, and irinotecan. |
Panitumumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must not match any of the following:
BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
| Note: Recommended for tumors with wild-type KRAS/NRAS (codons 12, 13, 59, 61, 117, and 146), and absence of BRAF V600E. |
| Biomarker Criteria: | Clinical Setting(s): Metastatic (BNF) |
| Note: Recommended as first-line therapy with wild-type KRAS/NRAS (codons 12, 13, 59, 61, 117, and 146), and for later lines of therapy if also negative for BRAF V600E. |
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely. Joint guidance from ASCO, AMP, CAP, and ASCP makes no recommendation for or against BRAF status as a predictive molecular biomarker, citing insufficient evidence. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely. The detected alteration (V600_K601delinsE) includes the V600E change plus a deletion of the adjacent amino acid, and in vitro evidence identifies it as a gain of function mutation, similar to V600E alone. Joint guidance from ASCO, AMP, CAP, and ASCP makes no recommendation for or against BRAF status as a predictive molecular biomarker, citing insufficient evidence. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (MCG) |
| Note: Preclinical studies and limited retrospective data suggest that KRAS amplification confers resistance to anti-EGFR antibodies. |
Pembrolizumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Approved for unresectable or metastatic, microsatellite instability-high or mismatch repair deficient colorectal cancer, for first line treatment or after progression following a fluoropyrimidine, oxaliplatin, and irinotecan. |
Vemurafenib +
Cetuximab + Encorafenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: FDA approved for metastatic colorectal cancer with a BRAF V600E mutation after prior therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely, unless given with a BRAF inhibitor. The detected alteration (V600_K601delinsE) includes the V600E change plus a deletion of the adjacent amino acid, and in vitro evidence identifies it as a gain of function mutation, similar to V600E alone. |
Encorafenib + Panitumumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely, unless given with a BRAF inhibitor |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Per NCCN, BRAF V600E mutation makes response to panitumumab or cetuximab unlikely, unless given with a BRAF inhibitor. The detected alteration (V600_K601delinsE) includes the V600E change plus a deletion of the adjacent amino acid, and in vitro evidence identifies it as a gain of function mutation, similar to V600E alone. |
Ipilimumab + Nivolumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Approved for patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a uoropyrimidine, oxaliplatin, and irinotecan. |
Lapatinib + Trastuzumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Clinical Setting(s): Metastatic (NCCN) |
| Note: NCCN recommended as subsequent line therapy. |
Pertuzumab + Trastuzumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Clinical Setting(s): Metastatic (NCCN) |
| Note: NCCN recommended as subsequent line therapy. |
Clinical Trials
There are 361 clinical trials for colorectal carcinoma, of which 248 are open and 113 are completed or closed. Of the trials that contain colorectal carcinoma as an inclusion criterion, 2 are early phase 1 (2 open), 162 are phase 1 (108 open), 85 are phase 1/phase 2 (65 open), 93 are phase 2 (55 open), 2 are phase 2/phase 3 (2 open), 12 are phase 3 (11 open), and 5 are no phase specified (5 open).
Microsatellite, MSH2, and MSH6 are the most frequent gene inclusion criteria for colorectal carcinoma clinical trials [3].
Pembrolizumab, nivolumab, and cetuximab are the most common interventions in colorectal carcinoma clinical trials.
Significant Genes in Colorectal Carcinoma
ABL2 +
ABL2 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ABL2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
ACVR1B +
ACVR1B is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
AKT1 +
AKT1 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain AKT1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
AKT2 +
AKT2 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain AKT2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].
AKT3 +
AKT3 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain AKT3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].
ALK +
ALK is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ALK status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (2 open) [3].
APC +
APC is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
ARAF +
ARAF is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARAF status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
ARID1A +
ARID1A is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ARID1A status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
ASXL1 +
ASXL1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
ATM +
ATM is an inclusion eligibility criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ATM status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
ATR +
ATR is an inclusion eligibility criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ATR status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
ATRX +
ATRX is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATRX status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
BARD1 +
BARD1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BARD1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
BLM +
BLM is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
BRAF +
BRAF is an inclusion eligibility criterion in 27 clinical trials for colorectal carcinoma, of which 15 are open and 12 are closed. Of the trials that contain BRAF status and colorectal carcinoma as inclusion criteria, 13 are phase 1 (8 open), 4 are phase 1/phase 2 (2 open), 8 are phase 2 (3 open), and 2 are phase 3 (2 open) [3].
Cetuximab, encorafenib, and panitumumab have evidence of efficacy in patients with BRAF mutation in colorectal carcinoma [3].
BRCA1 +
BRCA1 is an inclusion eligibility criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain BRCA1 status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
BRCA2 +
BRCA2 is an inclusion eligibility criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain BRCA2 status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
BRIP1 +
BRIP1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRIP1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
BTRC +
BTRC is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
C11ORF30 +
C11orf30 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain C11orf30 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
CCND1 +
CCND1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CCND1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [3].
CCND2 +
CCND2 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND2 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
CCND3 +
CCND3 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND3 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
CCNE1 +
CCNE1 is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CCNE1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
CCNE2 +
CCNE2 is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CCNE2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].
CDK12 +
CDK12 is an inclusion eligibility criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain CDK12 status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
CDK2 +
CDK2 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK2 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].
CDK4 +
CDK4 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CDK4 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [3].
CDK6 +
CDK6 is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDK6 status and colorectal carcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].
CDKN1A +
CDKN1A is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CDKN1A status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].
CDKN1B +
CDKN1B is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CDKN1B status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].
CDKN2A +
CDKN2A is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 1 is open and 2 are closed. Of the trials that contain CDKN2A status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [3].
CHD4 +
CHD4 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
CHEK1 +
CHEK1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CHEK1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
CHEK2 +
CHEK2 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CHEK2 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
CRKL +
CRKL is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain CRKL status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].
CSF1R +
CSF1R is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CTNNB1 +
CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CYLD +
CYLD is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CYLD status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
DICER1 +
DICER1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DICER1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
DNMT3A +
DNMT3A is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
DVL1 +
DVL1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
EGFR +
EGFR is an inclusion eligibility criterion in 6 clinical trials for colorectal carcinoma, of which 5 are open and 1 is closed. Of the trials that contain EGFR status and colorectal carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 2 are phase 2 (2 open) [3].
EPCAM +
EPCAM is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is an inclusion eligibility criterion in 16 clinical trials for colorectal carcinoma, of which 12 are open and 4 are closed. Of the trials that contain ERBB2 status and colorectal carcinoma as inclusion criteria, 5 are phase 1 (3 open), 5 are phase 1/phase 2 (4 open), and 6 are phase 2 (5 open) [3].
Fam-trastuzumab deruxtecan, lapatinib, trastuzumab, and pertuzumab have evidence of efficacy in patients with ERBB2 mutation in colorectal carcinoma [3].
ERBB3 +
ERBB3 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
ERCC2 +
ERCC2 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERCC2 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
ERCC3 +
ERCC3 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERCC3 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
ERCC4 +
ERCC4 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERCC4 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
ERCC5 +
ERCC5 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERCC5 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
ERCC6 +
ERCC6 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERCC6 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
EXO1 +
EXO1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
EZH2 +
EZH2 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
FANCA +
FANCA is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCA status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
FANCB +
FANCB is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCB status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
FANCC +
FANCC is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCC status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
FANCD2 +
FANCD2 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCD2 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
FANCE +
FANCE is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCE status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
FANCF +
FANCF is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCF status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
FANCG +
FANCG is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCG status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
FANCI +
FANCI is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCI status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
FANCL +
FANCL is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCL status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
FANCM +
FANCM is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCM status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
FGFR1 +
FGFR1 is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR1 status and colorectal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
FGFR2 +
FGFR2 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
FGFR3 +
FGFR3 is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and colorectal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
FLT1 +
FLT1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT3 +
FLT3 is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
FLT4 +
FLT4 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FZD1 +
FZD1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD10 +
FZD10 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD2 +
FZD2 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD3 +
FZD3 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD4 +
FZD4 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD5 +
FZD5 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD6 +
FZD6 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD7 +
FZD7 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD8 +
FZD8 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD9 +
FZD9 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
GATA3 +
GATA3 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
GNA11 +
GNA11 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains GNA11 status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
GNAQ +
GNAQ is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains GNAQ status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HDAC1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HDAC2 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
HGF +
HGF is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
HRAS +
HRAS is an inclusion eligibility criterion in 16 clinical trials for colorectal carcinoma, of which 12 are open and 4 are closed. Of the trials that contain HRAS status and colorectal carcinoma as inclusion criteria, 10 are phase 1 (8 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (2 open) [3].
IDH1 +
IDH1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
KDM6A +
KDM6A is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
KDR +
KDR is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
KEAP1 +
KEAP1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
KIT +
KIT is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
KMT2D +
KMT2D is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
KRAS +
KRAS is an inclusion eligibility criterion in 44 clinical trials for colorectal carcinoma, of which 32 are open and 12 are closed. Of the trials that contain KRAS status and colorectal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 25 are phase 1 (18 open), 11 are phase 1/phase 2 (9 open), 6 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].
LRP5 +
LRP5 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
LRP6 +
LRP6 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAGI2 +
MAGI2 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAGI2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
MAP2K1 +
MAP2K1 is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MAP2K2 +
MAP2K2 is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MAP2K3 +
MAP2K3 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAP2K4 +
MAP2K4 is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K4 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MAP2K5 +
MAP2K5 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K5 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAP2K6 +
MAP2K6 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K6 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAP2K7 +
MAP2K7 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K7 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAP3K1 +
MAP3K1 is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MAP3K1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].
MAPK1 +
MAPK1 is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAPK1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
MAPK3 +
MAPK3 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MCL1 +
MCL1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCL1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MCPH1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
MDM2 +
MDM2 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MDM2 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
MDM4 +
MDM4 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MDM4 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
MED12 +
MED12 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
MET +
MET is an inclusion eligibility criterion in 8 clinical trials for colorectal carcinoma, of which 4 are open and 4 are closed. Of the trials that contain MET status and colorectal carcinoma as inclusion criteria, 6 are phase 1 (2 open) and 2 are phase 2 (2 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MLF1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
MLH1 +
MLH1 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MLH1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
MLH3 +
MLH3 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MLH3 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
MRE11A +
MRE11A is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MRE11A status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
MSH2 +
MSH2 is an inclusion eligibility criterion in 6 clinical trials for colorectal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain MSH2 status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (1 open) [3].
MSH3 +
MSH3 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MSH3 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
MSH6 +
MSH6 is an inclusion eligibility criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain MSH6 status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
MST1R +
MST1R is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MTOR +
MTOR is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain MTOR status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
MUTYH +
MUTYH is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MUTYH status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
MYC +
MYC is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 1 is open and 2 are closed. Of the trials that contain MYC status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (1 open) [3].
NBN +
NBN is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain NBN status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
NF1 +
NF1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NF1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
NF2 +
NF2 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
NOTCH1 +
NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
NOTCH2 +
NOTCH2 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
NPM1 +
NPM1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NPM1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
NRAS +
NRAS is an inclusion eligibility criterion in 23 clinical trials for colorectal carcinoma, of which 16 are open and 7 are closed. Of the trials that contain NRAS status and colorectal carcinoma as inclusion criteria, 14 are phase 1 (10 open), 4 are phase 1/phase 2 (3 open), and 5 are phase 2 (3 open) [3].
NRG1 +
NRG1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
NSD1 +
NSD1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
NTRK1 +
NTRK1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NTRK1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
NTRK2 +
NTRK2 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NTRK2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
NTRK3 +
NTRK3 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NTRK3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
PALB2 +
PALB2 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PALB2 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
PARP1 +
PARP1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PARP1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
PARP2 +
PARP2 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PARP2 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
PCNA +
PCNA is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PDGFRA +
PDGFRA is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PDGFRA status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
PDGFRB +
PDGFRB is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PIK3C2B +
PIK3C2B is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
PIK3CA +
PIK3CA is an inclusion eligibility criterion in 8 clinical trials for colorectal carcinoma, of which 4 are open and 4 are closed. Of the trials that contain PIK3CA status and colorectal carcinoma as inclusion criteria, 4 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
PIK3CB +
PIK3CB is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CB status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
PIK3CG +
PIK3CG is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3CG status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].
PIK3R1 +
PIK3R1 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PIK3R1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].
PIK3R2 +
PIK3R2 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3R2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].
PMS1 +
PMS1 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PMS1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
PMS2 +
PMS2 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PMS2 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
POLD1 +
POLD1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
POLE +
POLE is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain POLE status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
PPP2R1A +
PPP2R1A is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PPP2R1A status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PPP2R2A status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
PRKCA +
PRKCA is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCA status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCB +
PRKCB is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCB status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCD +
PRKCD is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCD status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCE +
PRKCE is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCE status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCG +
PRKCG is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCG status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCI +
PRKCI is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCI status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCQ +
PRKCQ is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCQ status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PRKCZ +
PRKCZ is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCZ status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PTCH1 +
PTCH1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
PTEN +
PTEN is an inclusion eligibility criterion in 6 clinical trials for colorectal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain PTEN status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [3].
PTPN11 +
PTPN11 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTPN11 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
RAD50 +
RAD50 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD50 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
RAD51 +
RAD51 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
RAD51B +
RAD51B is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51B status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
RAD51C +
RAD51C is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51C status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
RAD51D +
RAD51D is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51D status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
RAD54L +
RAD54L is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD54L status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
RAF1 +
RAF1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAF1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
RB1 +
RB1 is an inclusion eligibility criterion in 2 clinical trials for colorectal carcinoma, of which 0 are open and 2 are closed. Of the trials that contain RB1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].
RET +
RET is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and colorectal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
RFC1 +
RFC1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC2 +
RFC2 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC3 +
RFC3 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC4 +
RFC4 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC5 +
RFC5 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RICTOR +
RICTOR is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RICTOR status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [3].
RNF43 +
RNF43 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RNF43 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
ROS1 +
ROS1 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ROS1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [3].
RPA1 +
RPA1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA2 +
RPA2 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA3 +
RPA3 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA4 +
RPA4 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPTOR +
RPTOR is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RPTOR status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].
RSPO1 +
RSPO1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RSPO1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
RUNX1 +
RUNX1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SETD2 +
SETD2 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SETD2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SLX4 +
SLX4 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain SLX4 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
SMARCA4 +
SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SMARCB1 +
SMARCB1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain SMARCB1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
SOX9 +
SOX9 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SOX9 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SRC +
SRC is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
SSBP1 +
SSBP1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
STAG2 +
STAG2 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 2 are open and 2 are closed. Of the trials that contain STAG2 status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
STK11 +
STK11 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain STK11 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (1 open) [3].
TAF1 +
TAF1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
TBX3 +
TBX3 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TBX3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
TET2 +
TET2 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
TP53 +
TP53 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 1 is open and 3 are closed. Of the trials that contain TP53 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].
TSC1 +
TSC1 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain TSC1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
TSC2 +
TSC2 is an inclusion eligibility criterion in 4 clinical trials for colorectal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain TSC2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
UGT1A1 +
UGT1A1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains UGT1A1 status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
VHL +
VHL is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
WNT1 +
WNT1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
XPO1 +
XPO1 is an inclusion eligibility criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
XRCC1 +
XRCC1 is an inclusion eligibility criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain XRCC1 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
